Latest Breaking News On - Target action date - Page 1 : comparemela.com

Catalyst Pharmaceuticals, Inc : Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE

Catalyst Pharmaceuticals, Inc : Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesIhre chancenIndiens wirtschaftPatrickj mcenanyHealth canadaCatalyst pharmaceuticals incCatalyst pharmaceuticalsCatalyst or company nasdaqExchange commissionDrug administrationIndicated maximum daily doseLambert eaton myasthenicTarget action dateNew drug applicationPrescription drug user fee actNorth america

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL.

United statesPatrickj mcenanyCatalyst pharmaceuticalsHealth canadaCatalyst or company nasdaqExchange commissionCatalyst pharmaceuticals incDrug administrationIndicated maximum daily doseLambert eaton myasthenicTarget action dateNew drug applicationPrescription drug user fee actNorth americaDuchenne muscularFast track

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomHong kongUnited statesAl qahirahMark leeMediajun saitoAhcene djaballahBen atwell alex shawZhou yiAnnie chengMichael shiAwny farajallahGastroenterol hepatolJemma nashDrug administrationExchange commission

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

Hong kongUnited kingdomAl qahirahUnited statesZhou yiSara noonanJun saitoBen atwell alex shawMichael shiAwny farajallahPanmure gordonJemma nashAnnie chengAhcene djaballahMark leeGastroenterol hepatol

FDA Panel Votes Against Approval Of Intercept Pharma s Liver Disease Drug; Stock Down

A panel of advisers to the U.S. Food and Drug Administration voted against approving Intercept Pharmaceuticals' (ICPT) investigational treatment for Nonalcoholic steatohepatitis, a serious progressive liver disease.

Advisory committeeMore such health newsDrug administrationGastrointestinal drugs advisory committeeIntercept pharmaceuticalDrugs advisory committeePrescription drug user fee actTarget action dateFda panelHealth newsIntercept pharma